Navigation Links
Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
Date:12/5/2012

ne, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

Forward Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.  Unless otherwise noted, Amgen is providing this information as of Dec. 5, 2012, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those w
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
3. Amgen Announces 2012 Third Quarter Dividend
4. Amgen to Present at the Leerink Swann Global Healthcare Conference
5. Amgen to Acquire Micromet
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
8. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
9. Amgen Announces 2012 First Quarter Dividend
10. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
11. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... California (PRWEB) October 23, 2014 ... a specialty pharmaceutical company devoted to bringing new ... partnerships in 2015. , ViaDerma has developed an ... allows for rapid mass transfer of pharmaceutical active ... body to provide immediate localized therapy. The transdermal ...
(Date:10/25/2014)... 24, 2014 The Workgroup ... leading nonprofit authority on the use of health ... announces its appointment of four new co-chairs to ... leaders include:, ,     Peter Dumont, Senior ... Pupo, Specialist Leader, Deloitte Consulting LLP , ...
(Date:10/25/2014)... A new way to produce engineered skin not ... grafting technologies, it also speeds up the healing process, ... the October issue of STEM CELLS Translational Medicine, could ... result from severe burns and chronic wounds. , A ... These wounds heal by contraction, with epithelization (the process ...
(Date:10/25/2014)... ROCKVILLE, Md. , Oct. 24, 2014  RegeneRx Biopharmaceuticals, ... on data presented at the Fourth International Symposium on ... , Italy.  "When thymosin beta ... was injected into the peritoneal cavity in a rodent ... vessels and throughout the brain parenchyma (the functional tissue ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... 13 , - Regulated Information, ThromboGenics ... innovative treatments for vascular disease, eye disease and,cancer, ... three month period ended,31 March 2008., Prof. ... on,today,s announcement, said: "ThromboGenics, clinical development programs,are continuing ...
... Nile Therapeutics, Inc.,(Nasdaq: NLTX ), today announced that ... the Rodman & Renshaw 5th Annual Global Healthcare,Conference at ... Meridian Beach,Plaza Hotel in Monte Carlo, Monaco. Mr. Strumph ... of Nile,s current clinical development,programs., The presentation will ...
... Foam Technology with Improved Usability & ... ... Despite the high incidence,of women,s health conditions that require intra-vaginal drug ... survey,found that an alarming majority of women find their current treatment,options ...
Cached Biology Technology:ThromboGenics N.V. - Business Update 2ThromboGenics N.V. - Business Update 3ThromboGenics N.V. - Business Update 4ThromboGenics N.V. - Business Update 5ThromboGenics N.V. - Business Update 6ThromboGenics N.V. - Business Update 7Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 272% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds 2
(Date:10/22/2014)... 2014 The Nano-Bio Manufacturing Consortium (NBMC), an ... Laboratory (AFRL), has chosen a project proposed by the ... of Arizona College of Medicine – Tucson ... goal is to assess different sweat collection methods and ... sweat under a variety of human-body conditions, the results ...
(Date:10/18/2014)... Among a group of 2,000 patients referred for ... a potential molecular diagnosis for 25 percent, including ... and new mutations contributing to disease, according to ... study is being released to coincide with the ... Whole-exome sequencing analyzes the exons or coding regions ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... Standards and Technology (NIST) and the German national ... sensor to successfully track a human heartbeat, confirming ... in Applied Physics Letters, * the study ... resembling a clinical setting with the NIST mini-sensors, ...
... Earth,s radiation balance by interacting with solar radiation ... organic compounds are key players in new particle ... role as the newly formed particles cool our ... aerosol (SOA) particles formed from volatile compounds emitted ...
... CAOCT. 13, 2010 -- Alzheimer,s disease (AD) is an ... in its cause and progression. For example, the lipid-transport ... factor for AD, and apoE4 carriers account for 65󈞼% ... to the disease is unclear. Scientists at ...
Cached Biology News:NIST mini-sensor traces faint magnetic signature of human heartbeat 2New research results change the understanding of atmospheric aerosol properties and climate effects 2Gladstone scientists uncover mechanism for the major genetic risk factor of Alzheimer's disease 2
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... has been developed for use with ... of nonspecific background staining due to ... blocking peroxidase with hydrogen peroxide. ... combination with additional novel components to ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: